Experimental HIV vaccine regimen safe but ineffective, NIH study finds

Summary by Ground News

Johnson & Johnson’s JNJ, -1.51% experimental HIV vaccine is safe but not effective, and the late-stage study will be discontinued as a result of that finding, federal researchers said Wednesday.

Published 4 months ago · New Brunswick, United States

News Articles

More
Filters

All

Left

Center

Right

The Star Kuala Lumpur

U.S. experimental HIV vaccine regimen safe but ineffective: study

LOS ANGELES, Jan. 18 (Xinhua) -- A U.S. investigational HIV vaccine regimen was safe but did not provide protection against HIV acquisition, according to a release of the U.S. National Institute of Health (NIH) on Wednesday. Read full story

4 months ago·Malaysia

Read Full Article

Ommcom News

US Experimental HIV Vaccine Regimen Safe But Ineffective: Study

Los Angeles: A US investigational HIV vaccine regimen was safe but did not provide protection against HIV acquisition, according to a statement of the US

4 months ago·Bhubaneswar, India

Read Full Article

NBC News

Another major HIV vaccine trial fails

The Mosaico trial was halted early after its vaccine failed to prevent HIV in men who have sex with men and transgender people in the Americas and Europe.

4 months ago·United States

Read Full Article

News Medical

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

4 months ago·United States

Read Full Article

Medical Xpress

Experimental HIV vaccine regimen safe but ineffective, NIH study finds

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined. The HPX3002/HVTN 706, or "Mosaico," Phase 3 clinical trial began in 2019 and involved 3,900 volunteers ages 18 to 60 years in Europe, North America and South America. Based on the DSMB's recommendation, the…

4 months ago

Read Full Article

Science Daily

Experimental HIV vaccine regimen safe but ineffective

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined. The HPX3002/HVTN 706, or 'Mosaico,' Phase 3 clinical trial began in 2019 and involved 3,900 volunteers ages 18 to 60 years in Europe, North America and South America. Based on the DSMB's recommendation, the…

4 months ago·United States

Read Full Article